| scholarly article | Q13442814 |
| P50 | author | Emiel F M Wouters | Q89553449 |
| Dirkje Postma | Q13135289 | ||
| P2093 | author name string | Wim C J Hop | |
| Karin H Groenewegen | |||
| Pascal L M L Wielders | |||
| Noel J J Schlösser | |||
| COSMIC Study Group | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | inflammation | Q101991 |
| risk factor | Q1475848 | ||
| systemic inflammation | Q7663815 | ||
| P304 | page(s) | 350-357 | |
| P577 | publication date | 2008-01-15 | |
| P1433 | published in | Chest | Q5093377 |
| P1476 | title | Increased systemic inflammation is a risk factor for COPD exacerbations | |
| P478 | volume | 133 |
| Q37254511 | A pilot study to examine the effects of smoking cessation on serum markers of inflammation in women at risk for cardiovascular disease |
| Q38937853 | An ECLIPSE View of Alpha-1 Antitrypsin Deficiency |
| Q54549439 | An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. |
| Q64235328 | Biomarkers and clinical outcomes in COPD: a systematic review and meta-analysis |
| Q37994304 | Biomarkers in chronic obstructive pulmonary disease |
| Q37937720 | Biomarkers of therapeutic response in patients with chronic obstructive pulmonary disease: a critical review of the literature |
| Q37012728 | Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease |
| Q35637295 | COPD association and repeatability of blood biomarkers in the ECLIPSE cohort |
| Q36402823 | Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony |
| Q92195505 | Clinical Phenotypes, Comorbidities, and Exacerbations according to Serum 25-OH Vitamin D and Plasma Fibrinogen Levels in Chronic Obstructive Pulmonary Disease |
| Q34612842 | Clinical predictors of frequent exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD) |
| Q35782210 | Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis |
| Q59125694 | Defining the role of neutrophil-to-lymphocyte ratio in COPD: a systematic literature review |
| Q38203153 | Diagnostic morphology: biophysical indicators for iron-driven inflammatory diseases |
| Q37417522 | Differential assessment and management of asthma vs chronic obstructive pulmonary disease. |
| Q36980698 | Disproportionate utilization of healthcare resources among veterans with COPD: a retrospective analysis of factors associated with COPD healthcare cost |
| Q44675545 | Effects of self-regulation protocol on physiological and psychological measures in patients with chronic obstructive pulmonary disease. |
| Q45377444 | Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial |
| Q26764891 | Exacerbations of COPD |
| Q37731457 | Exposure to Ambient Particulate Matter Induced COPD in a Rat Model and a Description of the Underlying Mechanism |
| Q50883932 | Fetuin-A is associated with disease severity and exacerbation frequency in patients with COPD. |
| Q35822156 | Fibrinogen, chronic obstructive pulmonary disease (COPD) and outcomes in two United States cohorts |
| Q26777960 | Fine particulate matter in acute exacerbation of COPD |
| Q34252132 | Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation |
| Q35575654 | HIV Infection Is Associated With Increased Risk for Acute Exacerbation of COPD. |
| Q33739053 | Identification of thyroxine-binding globulin as a candidate plasma marker of chronic obstructive pulmonary disease |
| Q37142609 | Impact of lung function on exacerbations, health care utilization, and costs among patients with COPD |
| Q37242230 | Incidence of utilization- and symptom-defined COPD exacerbations in hospital- and population-recruited patients |
| Q48611059 | Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. |
| Q82468356 | Inhibiting nonmuscle myosin II impedes inflammatory infiltration and ameliorates progressive renal disease |
| Q34638204 | Inhibition of granulocyte migration by tiotropium bromide |
| Q55415106 | Is It Time to Change the Definition of Acute Exacerbation of Chronic Obstructive Pulmornary Disease? What Do We Need to Add? |
| Q38089196 | Mechanisms of acute exacerbation of respiratory symptoms in chronic obstructive pulmonary disease. |
| Q92068171 | Metabolic Syndrome in Early Chronic Obstructive Pulmonary Disease: Gender Differences and Impact on Exacerbation and Medical Costs |
| Q45939644 | Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. |
| Q46188247 | Oral hygiene, periodontal health and chronic obstructive pulmonary disease exacerbations |
| Q38823010 | Prediction and prevention of exacerbations and mortality in patients with COPD. |
| Q34287563 | Predictors of exacerbations in chronic obstructive pulmonary disease--results from the Bergen COPD cohort study |
| Q38621350 | Prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio for hospital mortality in patients with AECOPD. |
| Q37672908 | Relationship between metabolic syndrome and epicardial fat tissue thickness in patients with chronic obstructive pulmonary disease |
| Q40833745 | Risk factors associated with acute exacerbation of chronic obstructive pulmonary disease in HIV-infected and uninfected patients. |
| Q92068191 | Serum Alpha-1 Antitrypsin Levels and the Clinical Course of Chronic Obstructive Pulmonary Disease |
| Q41020098 | Serum CCL-18 level is a risk factor for COPD exacerbations requiring hospitalization |
| Q34636461 | Surfactant protein D, Club cell protein 16, Pulmonary and activation-regulated chemokine, C-reactive protein, and Fibrinogen biomarker variation in chronic obstructive lung disease |
| Q52599800 | The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial. |
| Q37732387 | The recent advances of phenotypes in acute exacerbations of COPD. |
| Q37422824 | Update in chronic obstructive pulmonary disease 2008. |
| Q34656726 | Update on the potential role of statins in chronic obstructive pulmonary disease and its co-morbidities. |
| Q36809938 | Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis |
| Q85045912 | [COPD: bronchial and systemic inflammation] |
Search more.